Radiation Therapy Plus Durvalumab for Tumor-Stage Cutaneous T-Cell Lymphoma

NCT03235869 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped The company pulled durvalumab from heme malignancies

Conditions

Cutaneous T Cell Lymphoma

Interventions

DRUG: Durvalumab
RADIATION: Radiation Therapy

Sponsor

University of Michigan Rogel Cancer Center